logo
Share SHARE
FONT-SIZE Plus   Neg

Gannett Q4 Results Top Estimates - Quick Facts

Gannett Co., Inc. (GCI) reported that its fourth-quarter net income attributable to the company declined to $103.09 million or $0.44 per share, from $116.94 million or $0.49 per share in the same quarter last year.

Results for the fourth quarter of 2012 included special charges affecting operating income. Non-cash asset impairments, efficiency-driven facility consolidation and workforce restructuring charges totaled $114.6 million.

Results for the fourth quarter of 2011 included special charges affecting operating income of $78.4 million.

Non-GAAP Income attributable to the company for the quarter increased 20.2 percent to $207.3 million from $172.4 million in 2011.

Excluding special items in both years, fourth quarter earnings per share were $0.89 in 2012 compared to $0.72 in the fourth quarter of 2011, a 23.6 percent increase. Analysts polled by Thomson Reuters expected the company to report earnings of $0.88 per share for the quarter. Analysts' estimates typically exclude special items.

Net operating revenue for the quarter rose 9.4% to $1.52 billion from $1.39 billion in the prior year quarter. Nine analysts had consensus revenue estimate of $1.49 billion for the quarter.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Shares of International Consolidated Airlines Group S.A. were gaining around 3 percent in London trading after the airline reported Friday higher profit in its second quarter, benefited by higher passenger revenues, despite weak cargo revenues. The company now expects low double digit percentage growth in pre-exceptional operating profit in 2016. Swiss banking giant UBS Group AG reported Friday a 14 percent decline in second quarter profit with weakness in net interest income. Looking ahead, the company said the difficult conditions continue to persist, yet the firm is well positioned to benefit from even a moderate improvement in conditions. UBS shares were gaining around 3 percent in the morning trading in Zurich. We are well into the third quarter and past the middle of the year and it is time to take stock of regulatory decisions awaiting some biotech stocks in August. Despite the uncertain macroeconomic environment, the markets have run up, with the S&P 500 Index making new highs session after session. Valuation concerns may keep traders at bay. However, the biotech space is a different cup of tea.
comments powered by Disqus
Follow RTT